Johnson & Johnson JNJ
NYSE JNJ
$272.38 -3.94 (-1.43%)
As of: Nov 5, 2026 · 3:59 PM EST

Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026)

Updated

Johnson & Johnson (JNJ) recorded Income from Continuing Operations of $210 million in Q3 2026, down 95.9% from $5.15 billion a year earlier and down 96.2% from the prior quarter.

Analysis

Johnson & Johnson (JNJ) Income from Continuing Operations (2009 - 2026) Analysis & Trends

On a TTM basis, Johnson & Johnson's Income from Continuing Operations came in at $16.1 billion as of Sep 27, 2026, down 35.9% year-over-year; for FY2025, it was $26.8 billion, up 90.6% from FY2024.

  • Annual Income from Continuing Operations has a four-year compound annual growth rate of 16.2% (FY2021 to FY2025).
  • Across earlier years, Income from Continuing Operations came in at $14.07 billion in FY2024 (+5.6%), $13.33 billion in FY2023 (-18.6%), $16.37 billion in FY2022 and $14.71 billion in FY2021.
  • The Q3 2026 figure is the lowest quarterly Income from Continuing Operations since Q1 2023.
  • On a year-over-year basis, Income from Continuing Operations has declined for three consecutive quarters, with growth averaging 28.9% over the last eight quarters.
  • Peak year-over-year performance for Income from Continuing Operations in the last five years was growth of 237.9% in Q1 2025, against a decline of 95.9% in Q3 2026 at the low end.
  • Per Business Quant, the preceding three quarters came in at $5.53 billion (Q2 2026), $5.24 billion (Q1 2026) and $5.12 billion (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,221.09 Bn 1,194.71 Bn 20.46 Bn 6.45 Bn
2 Johnson & Johnson 656.38 Bn 576.24 Bn 17.30 Bn 210.00 Mn
3 AbbVie 510.79 Bn 478.80 Bn 13.12 Bn 4.22 Bn
4 Merck 363.00 Bn 317.38 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 313.89 Bn 287.12 Bn - -
6 Astrazeneca 290.02 Bn 263.91 Bn 13.26 Bn 4.80 Bn
7 Amgen 249.59 Bn 204.98 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 208.15 Bn 183.26 Bn 6.73 Bn 2.43 Bn
9 Pfizer 170.74 Bn 118.10 Bn 12.56 Bn 3.25 Bn
10 Vertex Pharmaceuticals 137.20 Bn 109.19 Bn 2.91 Bn 653.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 27, 2026 210.00 Mn
Jun 28, 2026 5.53 Bn
Mar 29, 2026 5.24 Bn
Dec 28, 2025 5.12 Bn
Sep 28, 2025 5.15 Bn
Jun 29, 2025 5.54 Bn
Mar 30, 2025 11.00 Bn
Dec 29, 2024 3.43 Bn
Sep 29, 2024 2.69 Bn
Jun 30, 2024 4.69 Bn
Mar 31, 2024 3.26 Bn
Dec 31, 2023 4.13 Bn
Oct 1, 2023 4.31 Bn
Jul 2, 2023 5.38 Bn
Apr 2, 2023 -491.00 Mn
Jan 1, 2023 3.23 Bn
Oct 2, 2022 4.31 Bn
Jul 3, 2022 4.26 Bn
Apr 3, 2022 4.57 Bn
Oct 3, 2021 3.67 Bn
API Access

Johnson & Johnson Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=JNJ&period=max&api_key=YOUR_API_KEY